Current Oncology (Dec 2021)

De-Escalating Breast Cancer Surgery: Should We Apply Quality Indicators from Other Jurisdictions in Canada?

  • Hannah Kapur,
  • Leo Chen,
  • Rebecca Warburton,
  • Jin-Si Pao,
  • Carol Dingee,
  • Urve Kuusk,
  • Amy Bazzarelli,
  • Elaine McKevitt

DOI
https://doi.org/10.3390/curroncol29010013
Journal volume & issue
Vol. 29, no. 1
pp. 144 – 154

Abstract

Read online

Quality Indicators (QIs), including the breast-conserving surgery (BCS) rate, were published by the European and American Breast Cancer Societies and this study assesses these in a Canadian population to look for opportunities to de-escalate surgery. A total of 2311 patients having surgery for unilateral, unifocal breast cancer between 2013 and 2017 were identified and BCS QIs calculated. Reasons for mastectomy had been prospectively collected with synoptic operative reporting. Our BCS rate for invasive cancer p < 0.001). Trend analysis looking at tumour size and medical need for mastectomy indicated that 80% of patients at our centre would be eligible for BCS with tumour cut off of 2.5 cm. Our institution met American but not European QI standards for BCS rates, potentially indicating a difference in patient demographics compared to Europe. Our results support the understanding that BCS rates are influenced by multiple factors and are challenging to compare across jurisdictions. CPM rates may offer a more actionable opportunity to de-escalate surgery for breast cancer.

Keywords